{"preliminary_commentary":{"by_channel":{"bluesky_thread":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT02254785","nct_id":"NCT02254785","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02254785. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Cabazitaxel","type":"EXPERIMENTAL"},{"description":null,"label":"Abiraterone or enzalutamide","type":"ACTIVE_COMPARATOR"}],"collaborators":["Sanofi","Ozmosis Research Inc."],"completion_date":{"date":"2020-05","type":"ESTIMATED"},"conditions":["Metastatic Castration-Resistant Prostatic Cancer"],"enrollment":{"count":120,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"cabazitaxel","otherNames":["Jevtana"],"type":"DRUG"},{"name":"Abiraterone","otherNames":["Zytiga"],"type":"DRUG"},{"name":"Enzalutamide 160mg daily (oral)","otherNames":["Xtandi"],"type":"DRUG"}],"last_update":"2017-12-06","lead_sponsor":"British Columbia Cancer Agency","official_title":"A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2020-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Clinical benefit rate","timeFrame":"12 weeks or more"}],"references":[{"citation":"Annala M, Fu S, Bacon JVW, Sipola J, Iqbal N, Ferrario C, Ong M, Wadhwa D, Hotte SJ, Lo G, Tran B, Wood LA, Gingerich JR, North SA, Pezaro CJ, Ruether JD, Sridhar SS, Kallio HML, Khalaf DJ, Wong A, Beja K, Schonlau E, Taavitsainen S, Nykter M, Vandekerkhove G, Azad AA, Wyatt AW, Chi KN. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021 Jul;32(7):896-905. doi: 10.1016/j.annonc.2021.03.205. Epub 2021 Apr 6.","pmid":"33836265","type":"DERIVED"}],"start_date":{"date":"2014-10"},"study_type":"INTERVENTIONAL","title":"Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT02254785"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02254785"}